Current and Emerging Therapies for COVID-19 in Lung Transplantation.

Daniel Z P FriedmanNatasha N PettitErica MacKenzieJennifer Pisano

Published in: Current pulmonology reports (2023)

Remdesivir remains an essential therapy for managing mild-moderate COVID-19. Though highly efficacious for mild-moderate COVID-19 for outpatient therapy, ritonavir-boosted nirmatrelvir has limited use in lung transplant recipients due to significant drug-drug interactions. Monoclonal antibodies, though useful, are the most affected by the emergence of new viral variants.

Keyphrases

sars cov
coronavirus disease
respiratory syndrome coronavirus
high intensity
emergency department
copy number
stem cells
antiretroviral therapy
bone marrow